| Scleroderma Medical News by Date | |
| July 2008 | |
| Effect of Increased Pigmentation on the Antifibrotic Response of Human Skin to UV-A1 Phototherapy. Clinical responses of sclerotic skin to UV-A1 phototherapy were modest because of UV-A1–induced skin darkening, which is photoprotective and attenuates antifibrotic responses. Arch Dermatol. 2008;144(7):851-858. (Also see: Morphea and Graft-vs-Host Disease ) | |
| Dartmouth researchers discover gene signatures for scleroderma. Distinct genetic profiles can discern different groups of patients with scleroderma. This discovery of distinguishing molecular subtypes within the disease offers new insight into the complexity of a poorly understood and hard to treat illness and opens a window for better diagnosis and targeted therapies. Genetic Engineering & Biotechnology News. July 15, 2008. (Also see: Causes of Scleroderma and Types of Scleroderma ) | |
| The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. In this nationwide register, a descriptive classification of patients with disease manifestations characteristic of SSc in five groups allows to include a broader spectrum of patients with features of SSc. Rheumatology 2008 47(8):1185-1192. (Also see: Type of Scleroderma ) | |
| Systemic sclerosis and its pulmonary complications in the Netherlands An epidemiological study. This study clarifies the epidemiology of SSc in the Netherlands and confirms the frequent occurrence of pulmonary complications, based on 654 cases. M C Vonk. Ann Rheum Dis. Published Online First: 29 May 2008. (Also see: Pulmonary Involvement ) | |
| New survey of 1000 patients highlights burden of disease in scleroderma. The results highlighted the need for greater support for patients from healthcare professionals with almost a third of respondents stating they were not aware of the type of scleroderma they have. The deadly nature of scleroderma means that it is crucial for patients to have a good understanding and education of the disease they are forced to live with every day. A.H. Mawdsley. PAR0015. EULAR 2008. (Also see: Physician/Patient Relationship ) | |
| L-tryptophan and scleroderma: Significance of nutritional supplements containing L-tryptophan. Our hypothesis though conjectural, mainly aims to highlight the possibility that a drug (L-tryptophan) known to cause a particular illness is available as part of an over-the-counter nutritional supplement in India. This drug has been banned in some countries. Feroze K, Venkitakrishnan S, Manoj J.J Postgrad Med 2008;54:235-6. (Also see: Causes of Scleroderma ) | |
| Ultraviolet Light Therapy Is as Beneficial for Darker Skin as Lighter Skin. An analysis of more than 100 patients has confirmed for the first time that darker-skinned patients benefit as those with lighter skin when given light therapy for morphea and related diseases. Newswise. UT Southwestern Medical Center. 07/08/08. (Also see: Skin Involvement and Morphea ) | |
| Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. KL-6, SP-D, vWF and ES (specific serum levels) are good surrogate factors of pulmonary fibrosis but can not replace conventional diagnostic procedures. However, these markers are suitable for the assessment of progression and severity of pulmonary fibrosis in systemic autoimmune disorders once the diagnosis is established. Clin Exp Rheumatol 2008; 26: 414-420. (Also see: Pulmonary Fibrosis ) | |
| Linear morphoea follows Blaschko's lines. Our data indicate that linear morphoea follows the lines of Blaschko. We hypothesize that in patients with linear morphoea susceptible cells are present in a mosaic state and that exposure to some trigger factor may result in the development of this condition. (PubMed) Br J Dermatol. 2008 Jul;159(1):175-81. (Also see: Morphea ) | |
| Pediatric morphea (localized scleroderma): Review of 136 patients. These data suggest an increased prevalence of morphea in Caucasian girls, and support methotrexate as treatment for problematic forms. (ScienceDirect). Journal of the American Academy of Dermatology. June 20, 2008. (Also see: Morphea ) | |
| Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. Patients with systemic autoimmune diseases cannot distinguish true comorbidities from conditions related to their index disease and, as such, a self-administered comorbidity questionnaire does not appear useful in these diseases. (PubMed). J Clin Epidemiol. 2008 Jul;61(7):654-62. (Also see: Difficult Diagnosis ) |

Hello, I am